Binding Characterization of Agonists and Antagonists by MCCS: A Case Study from Adenosine A2A Receptor
- PMID: 33856784
- DOI: 10.1021/acschemneuro.1c00082
Binding Characterization of Agonists and Antagonists by MCCS: A Case Study from Adenosine A2A Receptor
Abstract
Characterizing the structural basis of ligand recognition of adenosine A2A receptor (AA2AR) will facilitate its rational design and development of small molecules with high affinity and selectivity, as well as optimal therapeutic effects for pain, cancers, drug abuse disorders, etc. In the present work, we applied our reported algorithm, molecular complex characterizing system (MCCS), to characterize the binding features of AA2AR based on its reported 3D structures of protein-ligand complexes. First, we compared the binding score to the reported experimental binding affinities of each compound. Then, we calculated an output example of residue energy contribution using MCCS and compared the results with data obtained from MM/GBSA. The consistency in results indicated that MCCS is a powerful, fast, and accurate method. Sequentially, using a receptor-ligand data set of 57 crystallized structures of AA2ARs, we characterized the binding features of the binding pockets in AA2AR, summarized the key residues that distinguish antagonist from agonist, produced heatmaps of residue energy contribution for clustering various statuses of AA2ARs, explored the selectivity between AA2AR and AA1AR, etc. All the information provided new insights into the protein features of AA2AR and will facilitate its rational drug design.
Keywords: AA2A R; MCCS; protein fingerprint; residue energy contribution.
Similar articles
-
GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex.Proteins. 2010 Jan;78(1):197-211. doi: 10.1002/prot.22507. Proteins. 2010. PMID: 20063437 Free PMC article.
-
Integrating Pharmacophore into Membrane Molecular Dynamics Simulations to Improve Homology Modeling of G Protein-coupled Receptors with Ligand Selectivity: A2A Adenosine Receptor as an Example.Chem Biol Drug Des. 2015 Dec;86(6):1438-50. doi: 10.1111/cbdd.12607. Epub 2015 Jul 14. Chem Biol Drug Des. 2015. PMID: 26072970
-
Adenosine A2A receptor as a drug discovery target.J Med Chem. 2014 May 8;57(9):3623-50. doi: 10.1021/jm4011669. Epub 2013 Nov 15. J Med Chem. 2014. PMID: 24164628 Review.
-
Affinity Mass Spectrometry-Based Fragment Screening Identified a New Negative Allosteric Modulator of the Adenosine A2A Receptor Targeting the Sodium Ion Pocket.ACS Chem Biol. 2021 Jun 18;16(6):991-1002. doi: 10.1021/acschembio.0c00899. Epub 2021 May 28. ACS Chem Biol. 2021. PMID: 34048655
-
Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives.Curr Pharm Des. 2019;25(25):2716-2740. doi: 10.2174/1381612825666190716113444. Curr Pharm Des. 2019. PMID: 31333093 Review.
Cited by
-
How Do Modulators Affect the Orthosteric and Allosteric Binding Pockets?ACS Chem Neurosci. 2022 Apr 6;13(7):959-977. doi: 10.1021/acschemneuro.1c00749. Epub 2022 Mar 17. ACS Chem Neurosci. 2022. PMID: 35298129 Free PMC article.
-
Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?Int J Mol Sci. 2021 Nov 22;22(22):12569. doi: 10.3390/ijms222212569. Int J Mol Sci. 2021. PMID: 34830449 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources